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Objective: To examine relationships between cerebrospinal fluid (CSF) Alzheimer’
disease (AD) biomarkers and hypocretin-1 levels in patients with cognitive abnormalities
and hypocretin-deficient narcolepsy-cataplexy (NC), estimate diagnostic accuracy, and
determine correlations with sleep disturbances.
Background: Sleep disturbances are frequent in AD. Interactions between brain β-amyloid
(Aβ) aggregation and a wake-related neurotransmitter hypocretin have been reported in a
mouse model of AD.
Methods: Ninety-one cognitive patients (37 AD, 16 mild cognitive impairment—MCI
that converts to AD, 38 other dementias) and 15 elderly patients with NC were
recruited. Patients were diagnosed blind to CSF results. CSF Aβ42, total tau, ptau181, and
hypocretin-1 were measured. Sleep disturbances were assessed with questionnaires in
32 cognitive patients.
Results: Lower CSF Aβ42 but higher tau and P-tau levels were found in AD and MCI
compared to other dementias. CSF hypocretin-1 levels were higher in patients with
MCI due to AD compared to other dementias, with a similar tendency for patients
with advanced AD. CSF hypocretin-1 was significantly and independently associated with
AD/MCI due to AD, with an OR of 2.70 after full adjustment, exceeding that for Aβ42. Aβ42
correlated positively with hypocretin-1 levels in advanced stage AD. No association was
found between sleep disturbances and CSF biomarkers. No patients with NC achieved
pathological cutoffs for Aβ42, with respectively one and four patients with NC above tau
and P-tau cutoffs and no correlations between hypocretin-1 and other biomarkers.
Conclusions: Our results suggest a pathophysiological relationship between Aβ42 and
hypocretin-1 in the AD process, with higher CSF hypocretin-1 levels in early disease
stages. Further longitudinal studies are needed to validate these biomarker interactions
and to determine the cause-effect relationship and the role of wake/sleep behavior in
amyloid plaque regulation.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder that is
expected to become a disastrous worldwide epidemic within 40
years unless treatments to delay or halt the disease are devel-
oped. The pathological process is characterized by extracellular
aggregation of β-amyloid peptides (Aβ) produced by amyloid pre-
cursor protein (APP) overexpression in the senile plaques and
by intra-neuronal tau proteins in particular brain regions (Braak
and Braak, 1996; Duyckaerts et al., 2009). However, the mecha-
nisms of this pathological process remain only partly understood.
In recent years, there is growing evidence that circadian and
sleep disorders may play a causal role in the pathophysiology
of AD (Kang et al., 2009; Roh et al., 2012). Sleep disturbances
are frequently reported in AD, with both daytime sleepiness and
nighttime awakenings (Dauvilliers, 2007; Ju et al., 2013; Spira
et al., 2013). Non-specific factors associated with the ageing
process and more specific ones, including disrupted sleep and
circadian rhythm regulatory systems, are involved in sleep/wake
disturbances (Montplaisir et al., 1995; Dauvilliers, 2007; Ju et al.,
2013; Slats et al., 2013; Spira et al., 2013). Recently, interac-
tions between the amyloid process and the sleep-wake switching
system have been proposed. Brain interstitial fluid Aβ concen-
tration increased during wakefulness and decreased during sleep
in an APP transgenic mouse model of AD (Kang et al., 2009).
Similar data were found in young healthy subjects, with peak
CSF Aβ concentrations in the evening and lower concentrations
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overnight (Bateman et al., 2007; Kang et al., 2009). Further inter-
actions were reported between brain Aβ aggregation and the
wake-related neurotransmitter hypocretin/orexin in APP trans-
genic mice, with increased Aβ levels during hypocretin infusion
and decreased levels under the effect of a hypocretin receptor
antagonist (Kang et al., 2009). Significantly fewer hypocretin
neurons were found in the post-mortem hypothalami of AD
patients (Fronczek et al., 2012). However, several studies have
reported a normal range of CSF hypocretin-1 concentration
in AD patients (Mignot et al., 2002; Dauvilliers et al., 2003;
Baumann et al., 2004; Friedman et al., 2007). One elegant study
using an indwelling intrathecal catheter to collect hourly CSF
samples in six patients with AD and six controls reported a
correlation between hypocretin-1 and Aβ42, with no signifi-
cant between-group differences in hypocretin-1 circadian rhythm
amplitude (Slats et al., 2012). Moreover, lower CSF hypocretin-
1 levels were found in dementia with Lewy bodies compared
to AD and controls, with no associations between hypocretin-
1 and Aβ42 concentrations (Wennstrom et al., 2012). However,
CSF hypocretin-1 and tau levels were correlated in female non-
demented controls (Wennstrom et al., 2012). Thus, the relation-
ships between specific AD biomarkers and hypocretin-1 remain
unclear, as well as relationships between sleep/wake states and
brain Aβ fluctuations.
Our objective was to investigate the relationships between
CSF Aβ42, tau, P-tau, and hypocretin-1 in a large pop-
ulation of patients with cognitive abnormalities, including
patients at early and advanced stages of AD, patients affected
with other dementias, and hypocretin-deficient patients with
narcolepsy-cataplexy (NC).
MATERIALS AND METHODS
PATIENTS
One hundred and six unrelated patients (60 males, 46 females;
median age 69.3 years; range 32.1–89.5) participated. Patients
with cognitive abnormalities comprised a small randomized
sample from the Montpellier Cognitive biobank. Over 3000
baseline CSF samples were collected from patients attending
the Montpellier Neurological and Clinical Research Memory
Center (CMRR) for cognitive and behavioral disorders (offi-
cial registration No. DC-2008-417). All patients underwent an
extensive examination, including physical, neurological, and neu-
ropsychological assessments, laboratory tests, and brain imaging.
Diagnoses were performed blind to CSF results and by consen-
sus by a multidisciplinary team of neurologists, geriatricians,
and neuropsychologists. We selected 91 patients with cognitive
complaints, including 37 with AD, 16 with amnesic mild cog-
nitive impairment (MCI), and 38 with other dementias (DEM).
Patients with AD met NINCDS-ADRDA clinical diagnostic crite-
ria (McKhann et al., 1984, 2011). Patients with MCI initially met
the usual criteria established by Petersen et al. (1999). All subjects
that showed progressive cognitive decline to AD at a 2-to-7-year
follow-up were considered MCI due to AD. The DEM group
included frontotemporal lobar degeneration (FTLD) according to
consensus criteria (McKhann et al., 2001), dementia with Lewy
bodies (LBD) according to McKeith’s criteria (McKeith et al.,
1996; McKeith, 2006), and corticobasal degeneration according
to Boeve et al.’s criteria (Boeve et al., 1999). Dementia severity
was assessed using the Mini-Mental State Examination (MMSE)
(Folstein et al., 1975).
Elderly patients with typical NC (American Academy of Sleep
Medicine, 2005; Dauvilliers et al., 2007) who were followed at the
Sleep Unit and with available CSF were included (n = 15; 9males,
6 females; median age 65.6 years; range 54.0–86.4). Each patient
had been clinically diagnosed with NC by a sleep specialist based
on at least one night of polysomnographic recording followed
by the Multiple Sleep Latency Test (MSLT), HLA-DQB1∗0602
typing, and low CSF hypocretin-1 levels (<110 pg/mL) (Mignot
et al., 2002; Dauvilliers et al., 2003, 2007). No patients with NC
had cognitive abnormalities.
All patients gave their written informed consent to partici-
pate in the study. This study was approved by the regional ethics
committee of the University of Montpellier Hospital.
CSF SAMPLES AND ASSAYS
CSF was obtained after a median duration of one month
[interquartile range (IQR) 1–3 months] after diagnosis of cogni-
tive abnormalities, in contrast to NC, with more than 30 years of
delay between symptomonset and lumbar puncture in this elderly
population. CSF was collected in polypropylene tubes under stan-
dardized conditions, preferably between 11:00 a.m. and 1:00 p.m.
to minimize the influence of diurnal variation in CSF Aβ42 lev-
els. CSF samples were transferred within 4 h after collection and
centrifuged at 1000 g for 10min at 4◦C. A small amount of CSF
was used for routine analyses, including total cell count, bacte-
riological exam, and total protein and glucose levels. CSF was
aliquoted in polypropylene 1.5mL tubes and stored at −80◦C
until further analysis. CSF Aβ42, total tau, and phospho-tau-181
(P-tau) were measured with Innotest® sandwich ELISA according
to manufacturer’s procedures (Innogenetics, Ghent, Belgium).
The three biomarkers in each CSF sample were analyzed simul-
taneously. From these measurements, an Innotest® Amyloid Tau
Index (IATI) was calculated for each patient. We used validated
cutoffs for these biomarkers to clinically discriminate AD from
normal aging and other neurologic disorders (Hulstaert et al.,
1999).
Samples were rethawed for CSF hypocretin-1 measurement.
CSF hypocretin-1 (orexin-A) was determined in duplicate for all
subjects using I radioimmunoassay kits (Phoenix Peptide, Inc.)
according to manufacturer’s instructions. The detection limit was
10 pg/mL and intra-assay variability was <10%. CSF hypocretin-
1 levels <110 pg/mL were considered low, intermediate from 110
to 200, and normal at >200. All values were back-referenced to
Stanford reference samples (HHMI Stanford University Center
for Narcolepsy, Palo Alto CA) (Mignot et al., 2002). The biological
teams analyzed the CSF samples blind to clinical diagnosis.
SLEEP DISTURBANCES
To assess sleep disturbances, we conducted a short interview and
administered a sleep questionnaire in a subgroup of 32 patients
(n = 20 AD; n = 9 MCI due to AD; n = 3 DEM) within 2 years
after CSF lumbar puncture. Patients were asked to rate their sleep
duration based on bedtime, sleep latency, number of awaken-
ings during the night, duration of awakenings, estimated total
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duration of nighttime sleep hours, and estimated total duration
of wake time after sleep onset. The Epworth Sleepiness Scale was
used to assess daytime sleepiness. Sleep questionnaires were com-
pleted by patients with the help of caregivers when required,
especially for patients with AD and DEM.
STATISTICAL ANALYSIS
The sample is described in percentages for categorical variables
and median and range for quantitative variables (age, CSF mea-
surements), with distributions skewed using the Shapiro–Wilk
statistic. Chi-square tests or Kruskall–Wallis tests were used to
compare categorical and continuous characteristics between the
four groups (AD, MCI due to AD, DEM, and NC). Two-group
comparisons were performed using the Chi square (categor-
ical variable) and Mann–Whitney Test (continuous variable).
When comparisons were statistically significant, two-by-two
comparisons were performed using the Bonferroni correction.
Spearman’s rank order correlations were applied to determine
associations between two continuous variables. In order to deter-
mine which CSF measurements were independently associated
with AD + MCI due to AD, measurements were entered simul-
taneously into a logistic regression model with potential con-
founders (e.g., age). Associations were thus quantified with odds
ratios (OR) and their 95% confidence intervals (CI). Significance
level was set at p < 0.05. Statistical analyses were performed using
SAS, version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
DEMOGRAPHIC, CLINICAL, AND BIOLOGICAL RESULTS BY
DIAGNOSTIC CATEGORY
Results on the demographic, clinical, and biological variables
by diagnostic group are reported in Table 1. Significant group
differences were observed for age, with patients with AD being
the oldest and patients with NC the youngest. As expected,MMSE
Table 1 | Sociodemographic, clinical, and biological variables for patients with different etiologies of cognitive impairment and patients with
narcolepsy-cataplexy.
AD MCI due to AD DEM NC p-value p-valuea
N = 37 N = 16 N = 38 N = 15
Age (years) 72.30 [49.80–89.49] 73.20 [57.39–84.39] 66.84 [32.07–85.15] 65.59 [54.04–86.38] 0.03
Gender
Male 17 45.95 10 62.50 24 63.16 9 60.00 0.44
Female 20 54.05 6 37.50 14 36.84 6 40.00
MMSE 21.00 [2.00–25.00] 26.00 [26.00–30.00] 20.50 [9.00–30.00] 30.00 [30.00–30.00] <0.0001
MMSE
<26 35 100.00 0 0.00 29 80.56 0 0.00 <0.0001
≥26 0 0.00 14 100.00 7 19.44 15 100.00
CSF BIOMARKER MEASUREMENT
Aβ42 (pg/ml) 563.00 [232.00–1811.00] 593.00 [273.00–1505.00] 694.00 [306.00–1645.00] 947.00 [566.00–1332.00] 0.0005 0.02
Aβ42 (pg/ml)
≤500 14 37.84 5 31.25 8 21.05 0 0.00 NA NA
> 500 23 62.16 11 68.75 30 78.95 15 100.00
Tau (pg/ml) 579.00 [283.00–2165.00] 706.50 [343.00–1200.00] 264.50 [104.00–1200.00] 215.00 [69.00–633.00] <0.0001 <0.0001
Tau (pg/ml)
≥cutoff b 26 70.27 11 68.75 12 31.58 1 6.67 <0.0001
< cutoff 11 29.73 5 31.25 26 68.42 14 93.33
P-tau (pg/ml) 79.00 [20.00–215.00] 106.50 [46.00–215.00] 41.50 [8.00–156.00] 41.00 [19.00–92.00] <0.0001 <0.0001
P-tau (pg/ml)
≥60 32 86.49 14 87.50 7 18.42 4 26.67 <0.0001 <0.0001
<60 5 13.51 2 12.50 31 81.58 11 73.33
IATI index 0.62 [0.00–2.53] 0.60 [0.29–2.33] 1.28 [0.34–3.55] 1.76 [1.05–2.28] <0.0001 <0.0001
IATI index
<1 33 89.19 14 87.50 16 43.24 0 0.00 <0.0001 0.0009
≥1 4 10.81 2 12.50 21 56.76 15 100.00
Hypocretin-1 (pg/ml) 451.00 [199.00–672.50] 503.75 [299.00–628.50] 386.00 [273.00–574.00] 34.00 [10.00–108.00] 0.03 0.06
Hypocretin-1 (pg/ml)
<110 0 0.00 0 0.00 0 0.00 15 100.00 NA NA
110–200 1 2.70 0 0.00 0 0.00 0 0.00
≥200 36 97.30 16 100.00 38 100.00 0 0.00
aAdjusted for age.
b300 pg/ml (if aged 21–50 years), 450 (if aged 51–70 years), and 500 (if aged > 71 years).
NA, Not applicable.
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differed between groups, with scores for patients with either MCI
due to AD or NC above the cutoff of 26. No gender effect was
found on any CSF biomarker levels.
As expected, CSF hypocretin-1 levels differed between NC
and other diagnostic groups (p < 0.0001 for all comparisons),
with higher CSF hypocretin-1 levels in MCI due to AD, AD, and
DEM groups compared to NC. Of the patients with cognitive
abnormalities, CSF hypocretin-1 levels were higher in MCI due
to AD compared to DEM (p = 0.02), with a similar tendency
between AD and DEM (p = 0.06) (Figure 1). CSF biomarker lev-
els, including Aβ42, tau, P-tau, and IATI, differed significantly
between groups regardless of diagnostic category (continuous
and categorically validated cutoffs) (Table 1). More precisely,
CSF Aβ42 levels differed between the AD and NC (p < 0.0006)
and between the MCI due to AD and NC groups (p = 0.013).
Significant between-group differences were also found for CSF
tau, P-tau, and IATI levels in the AD vs. DEM, AD vs. NC,
MCI due to AD vs. DEM, and MCI due to AD vs. NC groups
(p < 0.006 for all comparisons after Bonferroni correction). No
patients with NC achieved pathological cutoffs for Aβ42 or IATI,
with respectively one and four patients with NC above tau
and P-tau cutoffs, all patients without cognitive abnormalities
(Table 1). One patient withMCI due to AD had intermediate CSF
hypocretin-1 levels, and no patients with either MCI due to AD,
AD, or DEM had low hypocretin-1 levels.
COMPARISONS BETWEEN THE AD AND MCI DUE TO AD AND DEM
GROUPS
Because no CSF biomarker levels differed between the AD and
MCI due to AD groups, and because follow-ups showed that all
MCI developed AD, we decided to pool these two groups into
one (AD+MCI-AD). The AD group included patients at early
stage (MCI due to AD) and advanced stage (AD per se) of a
similar disease. We further compared sociodemographic, clinical,
and biological characteristics of patients with AD+MCI-AD and
DEM (Table 2). A between-group age difference was found, with
older patients in the AD+MCI-AD group. All CSF biomarker lev-
els differed between groups, with lower Aβ42 and IATI and higher
tau and P-tau levels in the AD+MCI-AD group. CSF hypocretin-
1 levels also differed between groups, with higher levels in the
AD+MCI-AD group (Table 2).
Two multivariate logistic regression models were conducted to
determine the relative contribution of CSF biomarker measure-
ments to the AD+MCI-AD diagnosis. The first model included
hypocretin-1, tau, Aβ42, and age (Model 1), and the second
included hypocretin-1, P-tau, Aβ42, and age (Model 2) (Table 3).
After adjusting for these variables, hypocretin-1 levels remained
significantly and independently associated with AD+MCI-AD,
with an OR of 2.70 (95%CI = [1.37–5.32]) for Model 1 and an
OR of 2.66 (95%CI = [1.35–5.23]) for Model 2, exceeding that
for Aβ42 (Table 3).
CORRELATIONS BETWEEN CSF AD BIOMARKERS AND HYPOCRETIN-1
We found a positive correlation between hypocretin-1 levels
and Aβ42 (r = 0.43, p = 0.001) and the IATI index (r = 0.42,
p = 0.002) in the AD+MCI-AD group (n = 53). This can be
explained by the patient group with advanced AD (AD: r =
0.45, p = 0.005; MCI due to AD: r = 0.38, p = 0.15). No sig-
nificant correlations were found between hypocretin-1 and other
biomarkers in the DEM group. In the whole group of 91
FIGURE 1 | CSF measurement of hypocretin-1 in patients with Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), and with others Dementia
(DEM). Results are shown as a box-whisker plot, with median and 25th quartile of CSF hypocretin-1 levels.
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Table 2 | Comparison of sociodemographic, clinical, and biological variables between AD+MCI due to AD patients and patients with other
etiology of dementia.
DEM AD +MCI due to AD p-value p-valuea
N = 38 N = 53
Age (years) 66.84 [32.07–85.15] 72.58 [49.80–89.49] 0.02
Gender
Male 24 63.16 27 50.94 0.25
Female 14 36.84 26 49.06
MMSE 20.50 [9.00–30.00] 23.00 [2.00–30.00] 0.09
CSF BIOMARKER MEASUREMENT
Aβ42 (pg/ml) 694.00 [306.00–1645.00] 568.00 [232.00–1811.00] 0.01 0.03
Aβ42 (pg/ml)
≤500 8 21.05 19 35.85 0.13 0.19
>500 30 78.95 34 64.15
Tau (pg/ml) 264.50 [104.00–1200.00] 588.00 [283.00–2165.00] <0.0001 <0.0001
Tau (pg/ml)
≥cutoffb 12 31.58 37 69.81 <0.0001
< cutoff 26 68.42 16 30.19
P-tau (pg/ml) 41.50 [8.00–156.00] 82.00 [20.00–215.00] <0.0001 <0.0001
P-tau (pg/ml)
≥60 7 18.42 46 86.79 <0.0001 <0.0001
<60 31 81.58 7 13.21
IATI index 1.28 [0.34–3.55] 0.60 [0.00–2.53] <0.0001 <0.0001
IATI Index
<1 16 43.24 47 88.68 <0.0001 <0.0001
≥1 21 56.76 6 11.32
Hypocretin-1 (pg/ml) 386.00 [273.00–574.00] 486.50 [199.00–672.50] 0.004 0.005
Hypocretin-1 (pg/ml)
110–200 0 0.00 1 1.89 0.58 NA
≥200 38 100.00 52 98.11
aadjustment for age.
b300 pg/ml (if age between 21 and 50 years old), 450 (if age between 51 and 70 years old), and 500 (if age > 71 years old).
NA, Not applicable.
Table 3 | Multivariate logistic regression models of CSF biomarker measurements associated with Alzheimer’s Disease (AD)/Mild Cognitive
impairment due to AD.
Model 1 Model 2
Variables OR [95%CI]a Variables OR [95%CI]a
Hypocretin-1 (pg/ml) Hypocretin-1 (pg/ml)
OR for 110-unit increase 2.70 [1.37–5.32] OR for 110-unit increase 2.66 [1.35–5.23]
Tau (pg/ml) p-Tau (pg/ml)
OR for 300-unit increase 4.24 [2.03–8.84] OR for 60-unit increase 12.49 [3.61–43.23]
Aβ42 (pg/ml) Aβ42 (pg/ml)
OR for 500-unit increase 0.52 [0.20–1.33] OR for 500-unit increase 0.44 [0.17–1.14]
Age (years) Age (years)
OR for 10-year increase 2.15 [1.05–4.40] OR for 10-year increase 1.94 [0.96–3.92]
aAD + MCI due to AD vs. DEM.
cognitive patients, the expected negative correlations between
Aβ42 and tau (r = −0.3, p = 0.005) and between Aβ42 and P-
tau (r = −0.22, p = 0.04) were found, but not for hypocretin-1
levels. Unexpectedly, we found positive correlations between CSF
Aβ42 and tau (r = 0.69, p = 0.004) and P-tau (r = 0.70, p =
0.004) in patients with NC, but not for hypocretin-1 levels.
ASSOCIATIONS BETWEEN CSF BIOMARKERS AND SLEEP
DISTURBANCES
Sleep disturbances were assessed by clinical interview and ques-
tionnaires in a limited population sample (n = 32) with the help
of caregivers when required. The mean MMSE for the 20 AD
patients who completed sleep questionnaires is 19.9 [14–24], and
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21.6 [14–26] for the 3 DEM patients. No associations were found
between sleep disturbances (wake time after sleep onset, total
sleep time, and Epworth Sleepiness Scale) and CSF biomarkers
(Aβ42, tau, P-tau, and hypocretin-1) in either the whole assessed
population or in the AD+MCI-AD group only (n = 29).
DISCUSSION
We investigated the relationships between CSF Aβ42, tau, P-tau,
and hypocretin-1 levels in a large clinically based cohort
of patients with different etiologies of cognitive abnormali-
ties and hypocretin-deficient narcoleptic patients. Higher CSF
hypocretin-1 levels were found in all demented patients com-
pared to control narcoleptic patients without cognitive abnormal-
ities. More interestingly, CSF hypocretin-1 levels were higher in
patients with MCI due to AD compared to patients with other
etiologies of dementia, with a similar tendency for advanced AD.
Because all patients with MCI in our cohort evolved toward the
AD process, we pooled the AD patients into an early and advanced
stage AD group. Multivariate analysis results suggest that CSF
hypocretin-1 concentrations could contribute to the AD diagno-
sis, as significant levels were found in early stage AD. Moreover,
a positive correlation between Aβ42 and hypocretin-1 levels was
observed in advanced AD, with no association with sleep distur-
bances measured by sleep questionnaires only. Furthermore, no
association was found between CSF, tau, or P-tau and hypocretin-
1 levels.
CSF biomarkers are widely used for diagnosing AD in atypical
clinical forms and for differential and early diagnosis (Bateman
et al., 2007; Blennow and Zetterberg, 2009; Mattsson et al., 2009;
Gabelle et al., 2011). A major contribution of our study is that it
underscores the greater contribution of using hypocretin-1 com-
pared to Aβ42 to differentiate an AD + MCI due to AD diagnosis
from other dementia diagnoses. Although our results confirmed
that common amyloid and tau CSF biomarkers help diagnose AD
even at early stages, more interestingly, hypocretin-1 is signifi-
cantly and independently associated with this group of patients,
with an OR of 2.70 after full adjustment. The diagnostic interest
of hypocretin-1 is also highlighted by the fact that its CSF con-
centrations differed significantly between DEM andMCI patients
that converted into AD. This indicates that hypocretin-1 could
be used for early detection of AD. The underlying rationale is that
amyloid pathology is believed to be present very early in the devel-
opment of the disease, and Aβ42 and hypocretin were correlated
in AD. Previous studies have shown normal CSF hypocretin-1
levels in AD (Mignot et al., 2002; Dauvilliers et al., 2003), and
normal or low levels in LBD (Baumann et al., 2004; Wennstrom
et al., 2012). However, to our knowledge, none of these stud-
ies compared patients at different stages of the AD process, and
none specifically included patients affected with MCI. Between-
group comparisons of CSF hypocretin-1 levels in patients with
different etiologies of cognitive abnormalities are rare, and patho-
logical cutoffs for CSF hypocretin-1 levels have been validated
for narcolepsy only (Mignot et al., 2002; Dauvilliers et al., 2003,
2007). One study reported a 40% reduction in the total num-
ber of hypocretin neurons in AD (Fronczek et al., 2012), but
no correlation has yet been reported between CSF hypocretin-
1 levels and the number of hypocretin neurons in humans, as
surviving neurons might compensate for lost neurons by increas-
ing hypocretin synthesis.
Another striking finding of the present study is the positive
correlation between hypocretin-1 and Aβ42 levels in AD, but not
in other dementias or in NC. Because the patients with MCI were
seen regularly at the CMRR, with follow-up revealing conver-
sion to AD, we were able to determine largely pronounced brain
β-amyloid and hypocretin-1 interactions in advanced stage AD.
Using in vivo microdialysis in APP transgenic mice, a seminal
study highlighted significant interactions between brain extracel-
lular accumulations of Aβ peptide, wakefulness, and hypocretin-1
(Kang et al., 2009). The same authors recently demonstrated
a strong relationship between disrupted sleep-wake states and
increased wakefulness, loss of circadian Aβ fluctuation, and neu-
ronal activity (through lactate metabolism) in APP transgenic
mice only after amyloid plaque formation, and changes were
prevented by Aβ42 active immunization (Roh et al., 2012).
Human studies of CSF samples collected via lumbar catheters
in young healthy volunteers have revealed peak CSF Aβ con-
centrations in the evening and lower concentrations overnight
(Bateman et al., 2007; Kang et al., 2009). A slight correlation
between Aβ42 and hypocretin-1 levels was recently reported in 6
patients with AD and 6 healthy controls, with no between-group
difference in CSF hypocretin-1 levels and its circadian amplitude
(Slats et al., 2012). In contrast, no association between Aβ42 and
hypocretin-1 was reported in either control subjects or patients
with AD in a larger study, but with low hypocretin-1 levels in
9 female patients with LBD (Wennstrom et al., 2012). In young
patients with AD carrying presenilin mutations, CSF Aβ fluc-
tuation disappeared after amyloid plaque formation (Roh et al.,
2012). These varying results on relationships between brain Aβ
and hypocretin-1 levels across human studies may be due to
small sample sizes, differences in methodology and population
characteristics, and the influence of uncontrolled factors such as
sleep-wake states.
Sleep-wake behavior is a fundamental brain function that
is substantially associated with cognition and synaptic plastic-
ity (Tononi and Cirelli, 2006). A recent study in mice reported
that sleep is critical for ensuring metabolic homeostasis: large
increases in the cortical interstitial space during sleep result in
convective exchange between CSF and the interstitial fluid (Xie
et al., 2013). The restorative function of sleep may therefore be
related to increased clearance of potentially neurotoxic degrada-
tion products of neuronal activity that accumulate in the awake
brain, such as Aβ (Xie et al., 2013). Daytime wake and night-
time sleep fragmentation have been frequently reported in AD,
but with an unclear biological basis (Montplaisir et al., 1995;
Dauvilliers et al., 2003; Kang et al., 2009). Because hypocretin
is a major wake-related neurotransmitter (de Lecea et al., 1998),
few studies have focused on its impact on wakefulness consolida-
tion in either patients with AD (Friedman et al., 2007) or elderly
subjects (Ju et al., 2013; Spira et al., 2013). Using wrist actigra-
phy recording, one study reported increased wake fragmentation
in patients with lower CSF hypocretin-1 levels (Friedman et al.,
2007). A recent study revealed an association between CSF Aβ42
and poor sleep quality, but not sleep quantity, using actigraphy in
cognitively normal subjects potentially in the preclinical stage of
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AD (i.e., 50% having parental history of late-onset AD) (Ju et al.,
2013). Recently, a self-reported assessment of sleep parameters in
community-dwelling older adults showed that both shorter sleep
duration and poorer sleep quality were associated with greater Aβ
burden, measured by Pittsburgh compound B positron emission
tomography (Spira et al., 2013). Unfortunately, as in the previous
study, our protocol did not include actigraphy or polysomnog-
raphy recordings. To determine the impact of sleep/wake states
on the interaction between CSF Aβ42 and hypocretin-1 levels, we
determined the presence of sleep disturbances in a limited pop-
ulation sample using clinical interviews and questionnaires with
patients, with caregiver help when required. We found no asso-
ciations between total sleep time, wake time after sleep onset,
daytime sleepiness, and any CSF biomarkers. Further studies
using objective tools to assess sleep disturbances in patients with
AD are recommended as clinical interviews have limited value to
assess this condition.
The degeneration of key sleep and wake regulatory systems
in AD, which is responsible for a marked increase in nighttime
wakefulness and daytime sleepiness, may interfere with neu-
ronal metabolism per se and ultimately lead to Aβ aggregation.
Interestingly in AD, the decrease in CSF Aβ42 associated with its
aggregation in amyloid plaques is also correlated with other Aβ
isoforms, including Aβ40 and soluble APPs, which are released
mainly during physiological synaptic plasticity (Cole and Vassar,
2008; Gabelle et al., 2010). It is therefore possible that several fac-
tors believed to have a trophic function may play a role in this
pathophysiology, with potential relationships with sleep-wake
states (Friedman et al., 2007; Cole and Vassar, 2008; Xie et al.,
2013). Although the process is largely unclear, amyloid plaque for-
mation, a pathological hallmark of AD, may be modulated by the
endogenous hypocretin signal.
Another limitation of the present study is the absence of
healthy controls. However it was difficult to construct an appro-
priate control group of cognitively normal elderly adults with
CSF lumbar puncture. We used CSF samples from elderly patients
with NC characterized by daytime sleepiness, fragmented night-
time sleep, cataplexy, and particularly hypocretin deficiency.
As expected, CSF Aβ42, tau, P-tau, and IATI levels differed
significantly between AD, MCI due to AD, and NC groups.
However, patients with NC with low CSF hypocretin-1 levels did
not present low Aβ42 levels. Therefore, the positive correlation
between CSF Aβ42 and hypocretin-1 levels appears to be spe-
cific to the AD process. However, our results in NC contrasted
with a previous case report of a hypocretin-deficient young girl
with NC with low CSF Aβ42 who had been vaccinated for pan-
demic H1N1 (Kallweit et al., 2012). Unexpectedly, we also found
positive correlations between CSF Aβ42 and tau and P-tau lev-
els in patients with NC with no cognitive abnormalities, but no
relationship was found with hypocretin-1. These findings shed
light on the complex relationship between these biomarkers and
various underlying conditions.
To conclude, we examined CSF Aβ42, tau, P-tau, and
hypocretin-1 levels in a large clinically based population of
patients with cognitive abnormalities. Results indicate that
significantly higher CSF hypocretin-1 concentrations in early
stage AD could contribute to the AD diagnosis. These results also
suggest a pathophysiological relationship between a key wake-
related neurotransmitter (hypocretin-1) and brain accumulation
of β-amyloid peptides in the AD process. Further longitudi-
nal studies are required to validate these biomarker interac-
tions and to determine the cause-effect relationship and the
role of wake/sleep behavior in the regulation of amyloid plaque
formation.
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